Introduction
In 2012, visiting friends and relatives was the second most common reason for international travel among Canadian travellers and accounted for approximately two million overnight visits to overseas countries (1). Travellers intending to visit friends and relatives (VFRs) are a specific group identified as having an increased risk of travel-related morbidity. The United States Centers for Disease Control and Prevention define a VFR as "an immigrant, ethnically and racially distinct from the majority population of the country of residence (a higher-income country), who returns to his or her home country (lower-income country) to visit friends or relatives. Included in the VFR category are family members, such as the spouse or children who were born in the country of residence" (2). This is a summary of the CATMAT Statement on International Travellers Who Intend to Visit Friends and Relatives, in which a full description of the evidence and recommendations is available (3). The Statement focuses on the abovementioned definition of VFRs and outlines the increased risks faced by VFRs while providing recommendations based on the available literature. Given the current global patterns of population mobility, this definition of VFR may be rather strict. It is reasonable to extend these recommendations to all travellers to any country with an epidemiological gradient of risk compared to the country of residence, whose intent is to visit friends and relatives, regardless of migrant status or ethnicity (4, 5).
Methods
A literature search was conducted for both published studies and grey literature. MEDLINE, EMBASE, Global Health, Scopus, Google Scholar and Access MEDLINE databases were used as well as reports and publications from Statistics Canada, the Public Health Agency of Canada (PHAC) and Citizenship and Immigration Canada.
Based on this initial overview, section topics were selected and additional focused literature searches were performed. Literature and evidence from Canada regarding the epidemiology and burden of specific diseases in the VFR population was used when available. The Statement does not contain a comprehensive overview of all travel-related risks, as content was prioritized based on increased risk specifically for VFRs. Therefore, it is important to be familiar with and address all travel-related risks at destination with a special emphasis on the topics discussed below.
The Statement represents a narrative review of the travel medicine literature on VFRs as well as CATMAT expert opinion. The recommendations do not include a description of the strength of the recommendation or grade of the quality of evidence as in previous CATMAT statements. Previous CATMAT statements were referred to and reiterated where they related to VFRs and a comprehensive list of current CATMAT statements can be found on the PHAC travel health website (6).
Results and recommendations

Risk factors
Rates of travel-related illness in VFRs tend to be higher for many conditions due to several factors. VFRs have an increased potential for last-minute travel plans, often have longer stays, may be reluctant to eat differently than hosts, may stay in places without door or window screens and without bed nets, are often in close proximity to the local population and have an increased likelihood of drinking untreated water (7, 8) .
VFRs and foreign-born travellers are less likely to seek pre-travel health consultation (9, 10, 11, 12) , are more likely to seek advice closer to departure (13) and are more likely to decline a recommended vaccine (13). These differences have been associated with VFRs' low perception of personal disease risk (8), but may also reflect language, cultural and/or financial barriers preventing uptake (14, 15) . VFRs often believe that they are immune to diseases (such as malaria) in their home country (7, 14, 16) . They may seek advice from health care providers with a similar ethnic background who may not recommend preventive strategies such as chemoprophylaxis due to similar beliefs (17, 18) .
Malaria
Studies have found that among travellers with malaria, 59 to 99% did not use malaria chemoprophylaxis or took it inadequately (inappropriate drug or adherence) (19) . In a Canadian case series of malaria diagnoses, the majority of cases were among travellers who did not seek pre-travel advice and/or did not take appropriate malaria prophylaxis (20, 21) .
VFRs account for a significant proportion of imported malaria cases in non-endemic countries (19) . Studies have found foreign-born VFRs to have up to a 4.5-fold higher risk of contracting malaria than tourist travellers (22) . Based on data from the Canadian Malaria Network from 2001 to 2013, 45% of severe malaria cases in Canada, for which information was available, reported visiting friends and relatives as the purpose for travel (23).
Given the characteristics mentioned above that may increase the risk of malaria (such as personal perception of disease risk and immunity) VFRs should be counselled about the importance of malaria prevention when travelling to malaria-endemic countries. Recommendations should include use of personal protective measures to prevent mosquito bites and potential use of chemoprophylaxis, depending upon destination. VFRs should be advised to seek health care if they develop fever during travel or once they return to Canada.
Specific recommendations on malaria chemoprophylaxis are available in CATMAT's Canadian Recommendations for the Prevention and Treatment of Malaria (24).
Vaccine-preventable diseases
Due to variation in vaccination schedules or lack of access to vaccines in different countries, Canadian immigrants may be more susceptible to vaccine-preventable disease.
Routine immunization
Studies have found substantial rates of non-immunity to measles, mumps, rubella and varicella among Canadian immigrants from developing countries (25, 26, 27) . Foreign-born VFRs should be evaluated for immunization status and immunity to vaccine-preventable disease and routine vaccinations should be provided as needed. For pediatric VFRs, there may be an opportunity to accelerate the routine schedule in order to provide maximal protection during travel.
Appendix 2 in the full VFR Statement (3) and CATMAT's Statement on Pediatric Travellers (28) contain information on accelerated vaccination schedules for children.
Typhoid
The majority of cases of typhoid fever in North America are associated with travel, particularly travel to South Asia (Afghanistan, Pakistan, India, Nepal, Bangladesh, Maldives, Sri Lanka and Bhutan) (15). Studies have found VFR travel to be a major risk factor for travel-related typhoid fever infection, with VFRs accounting for 66% of cases in the United States (29) and more than 90% of cases in Quebec (30). A study by the global GeoSentinel network found VFRs to have a 7-fold greater risk of receiving a diagnosis of typhoid fever compared with tourist travellers (22).
Age-appropriate typhoid vaccination is recommended for VFRs travelling to South Asia (31). Typhoid vaccine is not routinely recommended for travellers to destinations outside of South Asia; however, it may be considered for VFRs in specific high-risk situations (31). Safe food and water precautions should be discussed and the importance of frequent hand washing should be emphasized.
Refer to CATMAT's Statement on International Travellers and Typhoid (31) for further information on prevention of typhoid fever and use of typhoid vaccine. risk of injury and/or contact with the medical system) and high levels of non-immunity would be considered specific risk factors for hepatitis B acquisition.
Those travelling to countries with poor sanitation and hygiene conditions should be advised to follow safe food and water precautions and to wash their hands frequently (37). VFRs travelling to HB-endemic countries or who may engage in behaviours increasing their risk for blood/body fluid contact should be counselled regarding safe practices (condom use, use of sterile medical equipment) (38). Travellers who are non-immune to HA and/or HB should be vaccinated prior to travel (37). Age-appropriate immunization is advised for children.
Further recommendations on prevention of HA and HB in travellers can be found in CATMAT's Summary of Recommendations for the Prevention of Viral Hepatitis During Travel (37).
Tuberculosis
Travellers to countries with higher tuberculosis (TB) incidence are at risk of acquiring infection during travel. Foreign-born individuals accounted for 64% of all reported cases in Canada in 2012, with the highest incidence rates among those originating from Africa, South-East Asia, Western Pacific and Eastern Mediterranean (39). These cases include TB disease acquired in the country of origin before immigration as well as during return VFR trips. Studies have found that significant proportions of TB in immigrant populations can be attributed to VFR travel (40, 41) . Additionally, foreign travel, especially VFR travel, has been found to be a risk factor for latent TB infection (LTBI) (42, 43) . VFRs travelling to high TB incidence countries should avoid consumption of unpasteurized dairy products to reduce the risk of M. bovis acquisition (44). VFRs should be cautioned to avoid individuals with unexplained chronic cough or known pulmonary TB until the individual is deemed non-infectious. Bacillus Calmette-Guérin (BCG) vaccine may be considered in certain circumstances for individual long-term travellers to high-prevalence countries (45).
Pre-and/or post-travel TB skin tests may be indicated depending on risk at destination, duration of travel and personal health factors. The full VFR Statement contains a decision making model to guide TB skin testing in travellers (3).
Refer to CATMAT's Risk Assessment and Prevention of Tuberculosis Among Travellers (44) for detailed guidance on pre-travel advice for TB infection risk avoidance and post-travel TB screening and to the Canadian Tuberculosis Standards (45) for up-to-date information on TB risk conditions and country-level risk stratification.
Parasitic infections
Certain parasitic infections, such as schistosomiasis, strongyloidiasis, echinococcosis and cysticercosis can be chronic and may cause significant morbidity and even death, while others are self-limiting and have a low impact on health. A Canadian GeoSentinel study found VFRs to be more likely to present with these and other parasitic infections (46) . VFRs should be advised to avoid freshwater activities (such as swimming) in regions where schistosomiasis is endemic (Africa, South-East Asia and parts of South America). Avoidance of skin-to-soil contact (such as walking barefoot) is recommended to prevent strongyloidiasis in tropical countries. Food and water precautions are recommended to prevent other parasitic infections spread via the fecal-oral route. The pre-travel assessment can provide an opportunity to identify risk and recommend screening for these treatable chronic parasitic infections among immigrants.
Sexually transmitted infections and Human Immunodeficiency Virus
New sexual partners and unprotected sexual encounters are common among travellers generally (47), including VFRs (48, 49) . A recent global GeoSentinel review found that VFR travel was associated with an increased risk of sexually transmitted infections (STI) compared with other travel (50) which adds to existing literature reports that STIs were more likely among VFRs than other travellers (22, 51) .
Sexual health counselling should be a routine part of the pre-travel consultation and risk of exposure to STIs and Human Immunodeficiency Virus (HIV) should be discussed. The importance of safer sex practices should be emphasized and travellers should be encouraged to bring condoms from Canada to assure their quality (52). HPV vaccine can be considered for adolescent and adult travellers not previously vaccinated. HB vaccination is recommended as above.
Refer to CATMAT's Statement on Travellers and Sexually Transmitted Infections (52) for additional recommendations related to STI risk reduction.
Injury
Injury is a significant cause of morbidity and mortality in travellers and accounts for 18%-25% of traveller mortality abroad (53, 54, 55) . Numerous characteristics of VFRs (longer trip duration, greater likelihood to use local modes of travel) are assumed to increase injury risk, though there is not specific literature on travel-related injury among VFRs.
Road safety precautions such as seatbelts, infant/child car seats and helmets should be recommended (56). VFRs should avoid riding motorcycles or bicycles and should be encouraged to use helmets where this cannot be avoided (56). For more information on injury risk and recommendations for prevention, refer to CATMAT's Statement on Risk of Injury and Travel (56).
Special populations
Pediatric VFRs
Compared to pediatric tourist travellers, pediatric VFRs are more likely to be younger, travel for longer periods, travel more often to rural areas, present for pre-travel advice closer to the departure date and travel to destinations with higher risk for tropical diseases (57, 58).
Pediatric VFRs have an increased risk of travel-related illness and are at particular risk for febrile illness (especially caused by malaria) (59), TB, typhoid and meningococcal meningitis (60). A recent surveillance study of pediatric VFRs from Canada found that enteric fever, malaria, diarrheal diseases and HA accounted for 75% of travel-related illnesses in this group (61). Only 26% of these travellers had received pre-travel advice.
These results emphasize the importance of pre-travel assessment and adherence to recommended interventions for children. Opportunities to accelerate the routine schedule should be evaluated in order to provide maximal protection during travel (refer to Appendix 2 of the full VFR Statement (3) for accelerated vaccination schedules) Parents should be advised that the rates of illness requiring hospitalization are higher among VFR children and that illness during and after travel requires urgent assessment. Also, parents of Canadian-born VFR children should be informed that their children do not have any innate immunity against travel-related illnesses due to genetics alone. For more information on pediatric travellers and recommendations, refer to CATMAT's Statement on Pediatric Travellers (28).
Immunocompromised and older VFRs
There is little research focusing on immunocompromised or older VFRs. Specific characteristics of these populations (comorbid conditions, poorer immune responses, contraindications to vaccines or frailty) which lead to increased health risks while travelling may lead to synergistic risks for VFRs.
Infectious disease risk should be reviewed with the traveller according to the degree of their immune compromise along with risks specific to the destination and appropriateness of travel.
For travel health information on immunocompromised travellers and detailed recommendations on specific conditions, refer to CATMAT's Statement on The Immunocompromised Traveller (62). For information on and recommendations for older travellers, refer to CATMAT's Statement on Older Travellers (63).
Targeting VFRs for pre-travel advice
Health care providers should discuss potential upcoming VFR travel with their patients at routine health visits. Consultation with a travel health specialist should be recommended for all VFRs and particularly for those with risk factors for severe disease. Because some patients may be unwilling or unable to afford the cost of seeking travel medicine consultation, primary care providers should equip themselves with travel health knowledge and clinical resources so they are able to provide appropriate essential recommendations.
Conclusion
The pre-travel consultation for VFRs provides an important opportunity for health promotion, identification of preexisting conditions and risk reduction. VFRs should be made aware of their increased risk for travel-related illnesses and how to prevent them. Higher levels of non-immunity to vaccine-preventable disease and increased prevalence of chronic diseases among VFRs should also be addressed. In addition, health care providers should stress the importance of adherence and address potential challenges to achieving it. Table 1 summarizes the disease-specific recommendations for VFRs and additional resources. Additional research is required to determine the facilitators and barriers for VFRs in accessing and adhering to pre-travel advice. Engaging ethnic communities and health care personnel that provide their care is necessary to assess knowledge, attitudes and behaviour regarding travel health and to determine optimal ways of providing information to VFRs. 
Statement on Meningococcal Disease and the International Traveller
McCarthy A 1 on behalf of the Committee to Advise on Tropical Medicine and Travel (CATMAT)*
Introduction
The goal of this Statement is to provide guidance to health care professionals for the prevention of meningococcal disease in international travellers from Canada.
Methods
This Statement was developed by a working group of the Committee to Advise on Tropical Medicine and Travel (CATMAT). It was developed to compliment a thorough literature review and analysis which was conducted as part of the development of the National Advisory Committee on Immunization's (NACI) recommendations in the Canadian Immunization Guide (1). CATMAT has considered the need for protection and the potential for adverse effects of vaccination. The Statement represents a narrative review of the travel medicine literature on meningococcal vaccines and CATMAT's expert opinion. The recommendations do not include a description of the strength of the recommendation or grade of the quality of evidence as has been done in previous CATMAT statements. Each member of CATMAT is a volunteer and none declared a relevant conflict of interest.
Background
Meningococcal disease is caused by a Gram negative bacterium, Neisseria meningitidis. Neisseria are divided into 12 serogroups according to the immunological reactivity of their capsular polysaccharide (2). The five major serogroups most commonly associated with invasive disease are A, B, C, Y and W-135 (2, 3, 4).
Person-to-person transmission occurs by close contact with respiratory secretions or saliva of infected persons (1, 4) . Humans are the only reservoir (5). Asymptomatic carriage occurs, and at any time, 5%-10% of the population may be carriers of N. meningitidis (1, 3, 4) . Invasive disease is an infrequent consequence of nasopharyngeal colonization (6).
Invasive meningococcal disease generally occurs one to fourteen days after exposure and usually presents as an acute febrile illness with rapid onset and features of meningitis or septicemia (meningococcemia), or both and a characteristic non-blanching petechial or purpuric rash. Symptoms of meningococcal meningitis include intense headache, fever, nausea, vomiting, photophobia and stiff neck. Meningococcemia often involves hypotension, acute renal failure, hemorrhage and multi organ failure (1, 4). Fatality rates are approximately five to ten percent even with prompt antimicrobial treatment in healthcare facilities (5). Up to one-third of survivors may have longterm sequelae including hearing loss, neurologic disabilities and digit or limb amputations (1, 2, 4).
Epidemiology
N. meningitidis is found worldwide. In most countries, N. meningitidis is recognized as a leading cause of meningitis and fulminant septicemia and is a significant public health problem. However, population-based surveillance with laboratory confirmation and strain characterization is still not attainable in many countries throughout the world (7). Surveillance data from many countries are incomplete or lacking and there is currently no reliable global burden estimate (8).
Meningococcal meningitis occurs globally and the predominant serogroup varies by geographic region. In Australia, New Zealand and Europe, serogroup B predominates, followed by serogroup C (7, 9) . Serogroups B and C predominate in the United States and Canada, followed by serogroup Y (7, 9) . The serogroup distribution across Latin America, South America and the Caribbean varies, with serogroups B and C predominating in some countries and W-135 and Y in others (9). Little is known about the epidemiology of meningococcal disease in Asia and neighbouring areas (7, 9) .
Different patterns of invasive meningococcal disease are seen across Africa (7). This is the case in the African meningitis belt, a region in sub-Saharan Africa extending from Senegal in the west to Ethiopia in the East (Figure  1) , with a population of approximately 400 million (10). During the dry season (approximately December through June), the incidence rate of meningococcal disease can reach as high as 1,000 cases per 100,000 population. In non-epidemic periods, the rate of meningococcal disease in this region is roughly five to ten cases per 100,000 population (4, 8). Risk is highest in travellers to the meningitis belt who have prolonged contact with local populations during an epidemic.
Because of the crowded conditions of the Hajj and Umrah pilgrimage to Saudi Arabia and high carrier rates of N. meningitidis among pilgrims, outbreaks of meningococcal disease have historically been a problem (4, 11). The Hajj pilgrimages in 2000 and 2001, for example, were associated with large outbreaks of serogroup W-135 in returning pilgrims and their contacts.
Although people of any age can develop disease, endemic disease occurs most often in children and adolescents, whereas in meningococcal epidemics, rates may rise in older children and young adults (1, 8). 
Figure 1: Map of African Meningitis Belt
Vaccine recommendations for Canadian travellers
Meningococcal vaccine recommendations vary by characteristics of the traveller (e.g., age, medical conditions, etc.) and the travel destination. Specific recommendations for travellers from Canada are outlined below. For healthy travellers to a destination where risk of meningococcal transmission is high, please see Table 1 in Part 4 Active Vaccines: Meningococcal Vaccine: Meningococcal Vaccine of the Canadian Immunization Guide for the vaccination schedules (1).
Routine vaccination programs with conjugate serogroup C vaccine have been implemented in every Canadian province and territory (1). Independent of travel plans, the traveller should be up-to-date for age in accordance with their provincial/territorial immunization schedule (12).
Travellers with underlying medical conditions
Vaccination is recommended for children and adults at increased risk of invasive meningococcal disease regardless of destination (Table 1) . Refer to the Canadian Immunization Guide for detailed information on recommended products, scheduling and dosage (1). 
Individuals between two months to less than two years of age 1
Men-C-ACYW-CRM (Menveo™) should be preferentially used.
For infants two months to less than one year of age, a schedule using two or three doses with each dose given eight weeks apart with another dose at 12 to 23 months of age is recommended (and at least eight weeks from the previous dose).
For children one to less than two years of age, a two-dose series is recommended with each dose given at least eight weeks apart.
Individuals between two months and 17 years of age
Multicomponent meningococcal serogroup B (4CMenB) vaccine should be considered.
For infants two to five months, three doses given with an interval of at least one month between doses is recommended. A fourth dose (a booster) is recommended between 12 and 23 months of age.
For infants six to 11 months, the first two doses should be separated by an interval of two months and a third dose is recommended between 12 and 23 months of age, no less than two months after the second dose.
For children one to ten years, two doses separated by a two month interval is recommended.
For individuals 11 to 17 years, two doses given at least one month apart is recommended.
Individuals two years of age and older 2
Any of the quadrivalent conjugate vaccines (Men-C-ACYW-135-CRM, Menveo™; Men-C-ACYW-135-D, Menactra®; or Men-C-ACYW-135-TT, Nimenrix™) can be given as a two-dose series at least eight weeks apart.
Individuals 18 to 55 years of age
The use of polysaccharide meningococcal vaccine is not routinely recommended in Canada. Conjugate vaccines possess significant advantages over polysaccharide vaccines including better immune memory, longer duration of efficacy, lack of hyporesponsiveness with booster doses and possible reduction of bacterial carriage rates (4, 5).
Booster doses 4 :
Booster doses should be given every five years after the last dose.
Booster doses:
Because of unknown duration of protection after immunization, the need for a booster dose is yet to be determined.
1 Based on available published data in this age group, Menveo™ should be used because it has been found to be safe and immunogenic. Routine meningococcal C conjugate vaccine does not need to be administered in addition to Menveo™. 2 Men-C-ACYW-135 vaccines are not authorized for use in those 56 years of age and older; however, based on limited evidence and expert opinion their use is considered appropriate (2). 3 In Canada, 4CMenB has been authorized for use in individuals from two months through 17 years of age. 4 The manufacturer of Nimenrix™ has not yet determined the need for a booster dose; however NACI recommends periodic booster for individuals at highrisk for IMD or who have ongoing risk of exposure (2).
Travellers to the Hajj and Umrah pilgrimages
In the aftermath of two large invasive meningococcal disease (IMD) outbreaks during the 2000 and 2001 pilgrimages, the Kingdom of Saudi Arabia Ministry of Health implemented a requirement for all pilgrims to receive meningococcal vaccine. A certificate of vaccination against meningococcal meningitis is required for all visitors arriving for the purpose of Hajj or Umrah. Hajj or Umrah visas cannot be issued without a valid proof of vaccination.
 Adults and children aged two years and older must be vaccinated with quadrivalent meningococcal vaccine (serogroups A, C, Y and W-135) (13).  Children between three months and two years of age must be vaccinated with two doses of meningococcal A vaccine, with a three-month interval between the two doses (13).  The vaccination must have been received not more than three years and not less than ten days before arrival in Saudi Arabia (13).
In general, travellers to this region do not need to receive 4CMenB vaccine unless there is evidence of a hyperendemic strain or an outbreak that is known to be caused by serogroup B that can be prevented by the vaccine.
Refer to the recommendations in the Government of Canada's travel health notices for pilgrims to the Hajj and Umrah posted each year in late summer to early fall for the most up-to-date information to ensure that individual travellers have appropriate vaccine documentation (14).
Travellers to sub-Saharan Africa
Quadrivalent meningococcal vaccine (serogroups A, C, Y, W-135) is recommended for travellers to the African meningitis belt (Figure 1) or countries outside the usual boundaries where epidemics have occurred, especially those who will be living or working there, or may be in close contact with the local population through school, accommodation, etc.
Immunization against serogroup C alone is not considered adequate for individuals travelling to this region. A single dose of any of the available quadrivalent conjugate meningococcal vaccines may be used for the immunization of individuals two years of age and older (2). Men-C-ACYW-135-CRM (Menveo™) is recommended for immunization of individuals two months to less than two years of age. Refer to the Canadian Immunization Guide for detailed information and schedules (1).
Other considerations for travellers
 Travellers to areas with current epidemics or heightened disease activity should be vaccinated, regardless of duration of exposure. The Government of Canada's travel health notices for recognized areas of new and recent meningococcal activity are released and updated regularly on travel.gc.ca (14).  IMD has historically occurred in schools, colleges and other places where large numbers of adolescents and young adults congregate. Individuals travelling to these settings may consider receipt of vaccine for serogroups B and A,C,Y, W-135 at least two weeks prior to arrival (5).  Individuals travelling to engage in research, industrial and/or clinical laboratory settings with the potential for routine exposure to N. meningitidis should be vaccinated with Men-C-ACYW-135 vaccine and 4CMenB vaccine. Re-vaccination of laboratory staff at ongoing risk of exposure should be done at routine five-year intervals (1). Laboratory staff at ongoing risk of exposure should be re-vaccinated at routine fiveyear intervals with Men-C-ACYW-135 vaccine (1). Because of unknown duration of protection after immunization, the need for a booster dose of 4CMenB vaccine is yet to be determined (9).  There is no evidence to recommend routine meningococcal immunization of individuals travelling to work as health care providers; nosocomial transmission of IMD is very uncommon (1).  Travellers to developed countries should follow the meningococcal immunization recommendations of the destination country (15). Table 2 identifies additional vaccine information, such as common adverse reactions, contraindications, precautions and use in special populations. For complete and detailed information, refer to the Canadian Immunization Guide (1).
Additional vaccine characteristics and usage
Table 2: Additional vaccine characteristics and usage recommendations for meningococcal vaccines
Vaccine feature Serogroup A, C, Y, W-135 vaccine Serogroup B vaccine
Adverse reactions
Mild injection site (e.g., redness, tenderness and swelling) and systemic reactions (e.g., headache, malaise) have been reported. Serious adverse events are rare.
Among infants and children up to 12 months of age, the most commonly reported adverse reactions included erythema, induration, fever and sleepiness or irritability. A review of the evidence can be found in the NACI Statement on the Advice for the use of 4CMenB Vaccine (9).
Contraindications and precautions
Contraindicated for individuals with a history of anaphylaxis after a previous dose of the vaccine or individuals with a proven anaphylactic reaction to any component of the vaccine or its container (1).
Administration of meningococcal vaccine should be postponed in
Contraindicated for individuals with a serious allergy to any vaccine component or previous dose (2). individuals with moderate or severe acute illness; individuals with minor acute illnesses (with or without fever) may be vaccinated (1).
Pregnancy and breastfeeding
Conjugate meningococcal vaccines have not been studied in pregnancy; however, the use of the vaccine may be considered, if indicated (1, 3). Inactivated vaccines, such as meningococcal vaccines, may be administered to women who are breastfeeding (1).
There are no studies of 4CMenB vaccine in pregnant or lactating women.
Immunocompromised travellers
Meningococcal vaccine is recommended for certain high-risk individuals as outlined above. When considering immunization of an immunocompromised person, consultation with the individual's attending physician may be of assistance. For complex cases, referral to a physician with expertise in immunization and/or immunodeficiency is advised.
Concurrent administration with other vaccines
Quadrivalent conjugate vaccines may be administered concomitantly with adolescent and adult ageappropriate vaccines at different injection sites using separate needles and syringes (1).
A review of the concomitant use of 4CMenB with other vaccines can be found in the NACI Statement on the Advice for the use of 4CMenB Vaccine (9).
Interchangeability of vaccines
Any of the quadrivalent conjugate vaccines may be used for revaccination, regardless of which meningococcal vaccine was used for initial vaccination (1). When possible, the infant series should be completed with the same vaccine.
Not applicable.
General precautions
Travellers should be advised to practice good hand hygiene interventions and avoid activities that promote the exchange of respiratory secretions, such as sharing drinks, cigarettes, lipstick, etc. Avoid overcrowding in confined spaces. Following close contact with an individual infected with meningococcal disease, medical advice should be sought regarding possible chemoprophylaxis and vaccination (5).
Conclusion
Meningococcal vaccination is the most effective measure for preventing IMD. The Government of Canada's travel health notices identify areas of new and recent meningococcal activity and are updated regularly (14). 
Ex-officio members:
Travel medicine resources for Canadian practitioners
Teitelbaum P 1 on behalf of the Committee to Advise on Tropical Medicine and Travel (CATMAT)*
Introduction
The goal of this document is to provide both the novice and the experienced travel medicine practitioner with a comprehensive (though not exhaustive) list of resources. Resources that appear to be most used by health professionals currently practising this specialty have been included. Select members of TravelMed, an international e-mail discussion forum for travel medicine practitioners, were informally canvassed and presented with a question regarding which travel medicine resources they find to be the most useful. Their responses informed the development of this Statement. In addition, the opinions of experts in travel medicine were solicited to identify resources.
The scope was international; however, particular attention was paid to Canadian sources of information. These are often more accessible to Canadian practitioners and reflect practice in this country.
Travel and tropical medicine frequently overlap. The intent of this document is to focus on travel medicine. Tropical medicine resources are cited mainly when they regularly include travel medicine material. 
Categories of resource
Online subscription services
These programs/services provide detailed assistance for any itinerary. The user inputs itinerary and traveller information. The program displays its recommendations regarding immunizations, malaria prophylaxis and advice. Generally, these resources can be very helpful for less-experienced practitioners. 
Outbreak reports and travel advisories
It is highly recommended that practitioners stay current regarding disease outbreaks of importance to travellers. The following sources provide up-to-date information that can be used in this regard. 
Certification
 The International Society of Travel Medicine holds at least one Certificate of Knowledge examination each year. It is held in conjunction with the biannual conference and regional meetings of the ISTM. Successful candidates are awarded a certificate attesting to proficiency in travel medicine. 
Conclusion
There are many Canadian and international resources available to inform Canadian travel medicine practitioners.
